Landos Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 8.9 million compared to USD 6.03 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.93 USD | +0.58% | -.--% | +526.50% |
Jun. 13 | AbbVie inks immune disorder drug licensing deal with China's FutureGen | RE |
May. 24 | Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+526.50% | 71.68M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024